美國處方藥價格
參考文獻

↑   (PDF).   [2020-10-04]. （原始内容 (PDF)存档于2021-02-16）.
1 2 3  Mulcahy, Andrew W.; Whaley, Christopher M.; Tebeka, Mahlet G.; Schwam, Daniel; Edenfield, Nathaniel; Becerra-Ornelas, Alejandro U. . RAND Corporation. 2021-01-28  [2021-02-23]. （原始内容存档于2021-04-29） （英语）.
↑  Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet. . JAMA. 23 August 2016, 316 (8): 858–71. PMID 27552619. doi:10.1001/jama.2016.11237.
1 2  Bach, Peter B.; Pearson, Steven D. . JAMA. 2015-12-15, 314 (23): 2503–2504. ISSN 1538-3598. PMID 26619354. doi:10.1001/jama.2015.16843.
↑  Morgan, Steven & Hurley, Jeremiah. . CMAJ. 2004-03-16, 170 (6): 945–946. PMC 359422 . PMID 15023915. doi:10.1503/cmaj.104001.
1 2 3  Kesselheim, Aaron S.; Avorn, Jerry; Sarpatwari, Ameet. . JAMA. 2016-08-23, 316 (8): 858–71. ISSN 0098-7484. PMID 27552619. doi:10.1001/jama.2016.11237 （英语）.
↑  . www.commonwealthfund.org.   [2017-05-01]. （原始内容存档于2018-06-14） （英语）.
↑  US Government Accountability Office (GAO) Prescription Drugs: Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004. （页面存档备份，存于） Report to Congressional Requesters. GAO-05-779. 15 August 2005.
↑  David Gross, Leigh Gross Purvis and Stephen W. Schondelmeyer,"Trends in Manufacturer Prices of Prescription Drugs Used by Older Americans" （页面存档备份，存于）, AARP, March 2007
↑  Joseph Antos and Thomas F. Wildsmith, "Inflated Claims about Drug Prices" 的存檔，存档日期2009-07-14., American Enterprise Institute, 8 July 2005
↑  Stolberg, Sheryl Gay. . The New York Times. 2019-12-12  [2021-01-29]. ISSN 0362-4331. （原始内容存档于2019-12-12） （美国英语）.
↑  Huetteman, Emmarie. . Kaiser Health News. 2019-07-25  [2021-01-29]. （原始内容存档于2021-03-24） （美国英语）.
↑  . POLITICO.   [2021-01-29]. （原始内容存档于2021-01-20） （英语）.
↑  . www.healthaffairs.org.   [2021-01-29]. doi:10.1377/hblog20190919.459441/full/. （原始内容存档于2020-09-27） （英语）.
↑  . medicare.com. 2014-11-13  [2016-10-22]. （原始内容存档于2020-11-02）.
↑  Manchikanti, Laxmaiah; Caraway, David; Parr, Allan; Fellows, Bert; Hirsch, Joshua. . Pain Physician. 2011, 14 (1): E35–67. PMID 21267047.
↑  .   [2020-10-04]. （原始内容存档于2021-03-16）.
↑  . New York Times. 17 January 2020  [23 February  2021]. （原始内容存档于2020-10-31）.
↑  The Editorial Board. . New York Times. 19 December 2015  [20 December 2015]. （原始内容存档于2020-12-20）.
↑  US Senate Special Committee on Aging. Collins, McCaskill open Senate investigation into Rx drug pricing, announce intention to hold hearings. November 4, 2015. Accessed 4 January 2016. （页面存档备份，存于）
↑  Duncan, Ian. . baltimoresun.com.   [2017-05-01]. （原始内容存档于2019-04-10） （美国英语）.
↑  Note.  (PDF). Harv. L. Rev. 2019, 132: 1748  [2020-10-04]. （原始内容 (PDF)存档于2020-08-07）. .
↑  Association for Accessible Medicines v. Frosh, 887 F.3d 664 (4th Cir. 2018).
↑  .   [2020-10-04]. （原始内容存档于2021-04-29）.
1 2  . The GoodRx Prescription Savings Blog. 2019-05-24  [2019-10-23]. （原始内容存档于2021-03-30） （美国英语）.
↑  .   [2020-10-04]. （原始内容存档于2020-07-26）.
↑  .   [2020-10-04]. （原始内容存档于2021-01-26）.
1 2  Pharmaceutical spending (indicator) （页面存档备份，存于）. OECD Data, Health resources. 2013 doi: 10.1787/998febf6-en, accessed 27 November 2015
↑   (PDF). CDC.   [2 December 2015]. （原始内容 (Table)存档于2020-10-30）.
↑  Martin, Anne B.; Lassman, David; Washington, Benjamin; the National Health Expenditure Accounts;  et al. . Health Affairs. 2012-01-01, 31 (1): 208–219. ISSN 0278-2715. PMID 22232112. doi:10.1377/hlthaff.2011.1135 （英语）.
↑  Cunningham, Peter J. . Health Affairs. 2010-05-01, 29 (5): 1037–1044. ISSN 0278-2715. PMID 20338908. doi:10.1377/hlthaff.2009.0493 （英语）.
1 2  Stagnitti, Marie N. Population Characteristics of Medicare Beneficiaries in the U.S. Civilian Noninstitutionalized Population, by Level of Annual Prescribed Medicines Expenses, 2003. Statistical Brief #138. September 2006. Agency for Healthcare Research and Quality, Rockville, MD. Web. 17 Sept. 2016.
↑   (PDF).   [2020-10-04]. （原始内容 (PDF)存档于2020-11-01）.
1 2  .   [2020-10-04]. （原始内容存档于2020-12-06）.
↑   (PDF).   [2020-10-04]. （原始内容 (PDF)存档于2021-03-08）.
↑  T., Folland, Sherman. . Goodman, Allen C. 1947-, Stano, Miron Eighth international. Londen ; New York. 2017. ISBN 9781138208049. OCLC 1002226694.
↑   (PDF).   [2020-10-04]. （原始内容 (PDF)存档于2021-03-30）.
↑  Chambers, James D.; Thorat, Teja; Pyo, Junhee; Chenoweth, Matthew; Neumann, Peter J. . Health Affairs. October 2014, 33 (10): 1751–1760. ISSN 0278-2715. PMID 25288419. doi:10.1377/hlthaff.2014.0574 .
↑  Chambers, James D.; Thorat, Teja; Pyo, Junhee; Chenoweth, Matthew; Neumann, Peter J. . Health Affairs. October 2014, 33 (10): 1751–1760. ISSN 0278-2715. PMID 25288419. doi:10.1377/hlthaff.2014.0574.
↑  Cunningham, Peter J. . Health Affairs. 2010-05-01, 29 (5): 1037–1044. ISSN 0278-2715. PMID 20338908. doi:10.1377/hlthaff.2009.0493 （英语）.
↑  http://www.washingtontimes.com, The Washington Times. . The Washington Times.   [2019-10-31]. （原始内容存档于2020-03-16） （美国英语）.
↑  .   [2015-11-27]. （原始内容存档于2020-11-02） （美国英语）.
↑  . www.cdc.gov.   [2018-04-10]. （原始内容存档于2021-02-23） （美国英语）.
1 2 3  Kennedy, Jae; Morgan, Steve. . Clinical Therapeutics. 2009, 31 (1): 213–219. PMID 19243719. doi:10.1016/j.clinthera.2009.01.006.
1 2 3 4  Kennedy, Jae; Morgan, Steve. . Clinical Therapeutics. 2006, 28 (8): 1217–1224. PMID 16982299. doi:10.1016/j.clinthera.2006.07.009.
↑  Hsu, John; Price, Mary; Huang, Jie; Brand, Richard; Fung, Vicki; Hui, Rita; Fireman, Bruce; Newhouse, Joseph P.; Selby, Joseph V. . New England Journal of Medicine. 2006-06-01, 354 (22): 2349–2359. ISSN 0028-4793. PMID 16738271. doi:10.1056/nejmsa054436.
↑  Chandra, Amitabh; Gruber, Jonathan; McKnight, Robin. . The American Economic Review. 2010, 100 (1): 193–213. JSTOR 27804926. PMC 2982192 . PMID 21103385. doi:10.1257/aer.100.1.193.
↑  Alexander GC, Long C, Kaestner R. . Medical Care Research and Review. December 1, 2016, 75.
↑  Flaherty, Mary Pat; Gaul, Gilbert M. . The Washington Post. 2003-10-23. ISSN 0190-8286. （原始内容存档于2020-10-30） （美国英语）.
↑  Morgan, Steven; Hurley, Jeremiah. . Canadian Medical Association Journal. 2004-03-16, 170 (6): 945–946. ISSN 0820-3946. PMC 359422 . PMID 15023915. doi:10.1503/cmaj.104001 （英语）.
↑  Cox C, Kamal R, Jankiewicz A, Rousseau D. https://jamanetwork.com/journals/jama/fullarticle/2510894 （页面存档备份，存于） JAMA. 2016;315(13):1326. doi:10.1001/jama.2016.2646. Web. 22 Mar 2019.
↑  Jaffe, Susan. . The Lancet. 28 November 2015, 386 (10009): 2127–2128. PMID 26638951. doi:10.1016/S0140-6736(15)01098-3.
↑  Ambrish Singh. 2017. Transparency in Drug Pricing - Is it a New Trend in Making? [Online] Available at: https://www.linkedin.com/pulse/transparency-drug-pricing-new-trend-making-ambrish-singh/ （页面存档备份，存于）. [Accessed 25 September 2017].
1 2  . www.iphandbook.org.   [2017-05-01]. （原始内容存档于2020-02-17）.
1 2  Ulwik, James.  (PDF). 2015. （原始内容 (PDF)存档于2016-08-20）.
↑  Dusetzina, Stacie B. . JAMA Oncology. July 2016, 2(7): 960–61  [2021-02-23]. （原始内容存档于2021-02-25） –JAMA Network.
↑  Schondelmeyer, Stephen W; Purvis, Leigh.  (PDF). AARP Public Policy Institute. December 2016  [7 December 2020]. （原始内容 (PDF)存档于2021-03-20）.
↑  . Democrats, Energy and Commerce Committee. 2017-03-02  [2020-12-07]. （原始内容存档于2021-03-25） （英语）.
↑  For instance, Valeant Pharmaceuticals’ acquisition strategy acquired 100 companies, and part of this strategy was to increase prices as the market was consolidated. See S. M. Collins and C. McCaskill, Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System (U.S. Senate, Special Committee on Aging, Dec. 2016).
↑  Poll Finds Nearly Three Quarters of Americans Say Prescription Drug Costs Are Unreasonable, and Most Blame Drug Makers Rather Than Insurers for the Problem （页面存档备份，存于） Kaiser Family Foundation. 16 June 2015, accessed 27 November 2015
↑  Erik Sherman. . CBS news. October 7, 2015  [2020-10-04]. （原始内容存档于2021-01-26）.
1 2 3  Greene, Jeremy A.; Anderson, Gerard; Sharfstein, Joshua M. . Journal of the American Medical Association. 2016, 31 (5): 461–462. PMID 26747694. doi:10.1001/jama.2015.18720.
↑  . www.cbsnews.com.   [2020-12-07]. （原始内容存档于2021-03-29） （美国英语）.
↑  Tami Luhby. . CNN.   [2020-12-07]. （原始内容存档于2021-01-25）.
↑  Allergan, “Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results,” January 29, 2019, available at https://www.allergan.com/investors/news/thomson-reuters/allergan-reports-fourth-quarter-and-full-year-2018.
1 2  Ledley, Fred D.; McCoy, Sarah Shonka; Vaughan, Gregory; Cleary, Ekaterina Galkina. . JAMA. 2020-03-03, 323 (9): 834  [2021-02-23]. ISSN 0098-7484. PMC 7054843 . PMID 32125401. doi:10.1001/jama.2020.0442. （原始内容存档于2021-04-29） （英语）.
↑  EST, Rosie McCall On 3/4/20 at 6:01 AM. . Newsweek. 2020-03-04  [2020-12-07]. （原始内容存档于2021-05-06） （英语）.
↑  Matthew Herper How To Charge $1.6 Million For a New Drug And Get Away With It. Forbes, Mar 19, 2012, accessed 2 December 2015 （页面存档备份，存于）
↑  . rarediseases.info.nih.gov.   [2020-10-04]. （原始内容存档于2021-03-18）.
1 2  . 2017-11-15  [2020-10-04]. （原始内容存档于2021-01-27）.
↑  .   [2020-10-04]. （原始内容存档于2021-04-28）.
↑  .   [2020-10-04]. （原始内容存档于2021-01-19）.
↑  .   [2020-10-04]. （原始内容存档于2019-10-30）.
↑  Silverman, Ed. . Stat. 2 March 2016  [17 August 2017]. （原始内容存档于2021-01-17）.
↑  Lee, Chia-Ying; Chen, Xiaohan; Romanelli, Robert J.; Segal, Jodi B. . Journal of Pharmaceutical Policy and Practice. 2016-01-01, 9: 26. ISSN 2052-3211. PMC 5034442 . PMID 27688886. doi:10.1186/s40545-016-0079-1.
↑  Morgenson, Gretchen. . The New York Times. 2017-04-14  [2017-05-01]. ISSN 0362-4331. （原始内容存档于2020-11-11）.
↑  . ASPE. 2015-06-13  [2017-05-01]. （原始内容存档于2021-03-18） （英语）.
↑  . NPR.org.   [2017-05-01]. （原始内容存档于2021-04-20） （英语）.
1 2 3  Research, Center for Drug Evaluation and. . www.fda.gov.   [2017-05-01]. （原始内容存档于2019-04-23） （英语）.
1 2  .   [2017-05-01]. （原始内容存档于2021-01-16） （英语）.
↑  FDA. FY 2014 Performance Report to the President and Congress for the Generic Drug User Fee Amendments. （页面存档备份，存于） FDA User Fee Reports, Accessed 4 January 2015.
↑  .   [2020-10-04]. （原始内容存档于2021-03-06）.
1 2  Implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) Testimony of Janet Woodcock, M.D.Director, Center for Drug Evaluation and Research U.S. Food and Drug Administration[] Before the Committee on Health, Education, Labor and Pensions. United States Senate, 18 pages, January 28, 2016.
↑  Nature Reviews Drug Discovery, 2004 (3), 711–716.
1 2  The Process of New Drug Discovery and Development （页面存档备份，存于） Second Edition, Charles G. Smith and James T. O'Donnell, Taylor & Francis, 2006, ISBN 0849327792, 9780849327797 688 pages, published by Informa Healthcare
↑  Herper, Matthew. . Forbes.   [29 March 2013]. （原始内容存档于2020-12-09）.
↑  Why Are Drug Prices So High? （页面存档备份，存于）, PSC/City University of New York
1 2  Brandon Kramer and Michael Shally-Jensen. Prescription Drug costs （页面存档备份，存于）. pp 273-283. in: Encyclopedia of Contemporary American Social Issues 4 volumes, ABC-CLIO, December 22, 2010, Social Science, 1707 pages, Santa Barbara
↑  Charles L. Hooper; David R. Henderson.  (PDF). Regulation. Cato Institute. 2016  [2020-10-04]. （原始内容 (PDF)存档于2019-08-02）.
↑  Jeanne Whalen. . Wall Street Journal. December 1, 2015  [2020-10-04]. （原始内容存档于2021-04-21）.
↑  . www.thepharmaletter.com.   [2019-12-29]. （原始内容存档于2020-11-01）.
↑   (PDF).   [2020-10-04]. （原始内容 (PDF)存档于2019-10-13）.
↑  Linda Cahn When Is a Brand a Generic? In a Contract With a PBM （页面存档备份，存于） Managed Care, September 2010. accessed 2 December 2015.
1 2  Jayne O'Donnell. . USA Today. 3 March 2014  [1 August 2016]. （原始内容存档于2020-11-06）.
↑  Matthew Herper. . Forbes. 10 May 2012  [2 December 2015]. （原始内容存档于2020-11-12）.
↑  Dusetzina, Stacie B.; Conti, Rena M.; Yu, Nancy L.; Bach, Peter B. . JAMA Internal Medicine. 2017-08-01, 177 (8): 1185–1188. ISSN 2168-6106. PMC 5722464 . PMID 28558108. doi:10.1001/jamainternmed.2017.1885.
↑  Thomas, Katie. . The New York Times. 2018-07-27  [2020-10-04]. （原始内容存档于2021-03-30）.
1 2  . NEJM Catalyst. 2016-01-13  [2017-10-30]. （原始内容存档于2019-10-30） （美国英语）.
↑  Office of Pharmacy Affairs. . Health Resources and Services Administration. n.d.  [2 December 2015]. （原始内容存档于2021-05-05）.
1 2  . Consumer Reports.   [2017-10-30]. （原始内容存档于2017-12-09） （美国英语）.
↑  . NPR.org.   [2017-10-30]. （原始内容存档于2020-11-01） （英语）.
↑  Starner CI, Alexander GC, Bowen K, Qui Y, Wickersham P, Gleason PP. . Health Affairs. Oct 2014, 33 (10): 1761–1769. PMID 25288420. doi:10.1377/hlthaff.2014.0497.
↑  Daubresse, Matthew; Andersen, Martin; Riggs, Kevin R.; Alexander, G. Caleb. . Pharmacotherapy. 2017-01-01, 37 (1): 12–24. ISSN 1875-9114. PMC 5243177 . PMID 27455456. doi:10.1002/phar.1802 （英语）.
↑  Grande, David. . JAMA. 2012-06-13, 307 (22): 2375–2376. ISSN 0098-7484. PMID 22692167. doi:10.1001/jama.2012.5603 （英语）.
↑  Ross, Joseph S.; Kesselheim, Aaron S. . New England Journal of Medicine. 2013-09-25, 369 (13): 1188–1189. PMID 23984672. doi:10.1056/nejmp1301993 （英语）.
1 2 3  Kang, So-Yeon; Bai, Ge; DiStefano, Michael J.; Socal, Mariana P.; Yehia, Farah; Anderson, Gerard F. . Annual Review of Public Health. 2020-04-02, 41 (1): 499–512  [2020-10-04]. ISSN 0163-7525. doi:10.1146/annurev-publhealth-040119-094305. （原始内容存档于2022-03-03） （英语）.
1 2  Research, Center for Drug Evaluation and. . www.fda.gov.   [2017-10-30]. （原始内容存档于2019-04-23） （英语）.
1 2  Schoonveld, Ed. . Gower Publishing, Ltd. 2015: 73–86. ISBN 978-1472438829.
↑  Mehrez, Abraham; Gafni, Amiram. . Medical Decision Making. 1989, 9 (2): 142–149. PMID 2501627. doi:10.1177/0272989x8900900209 （英语）.
↑  Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Blayney, Douglas W.; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell; Langdon, Robert; Lyman, Gary H. . Journal of Clinical Oncology. 2016-08-20, 34 (24): 2925–2934. ISSN 0732-183X. PMID 27247218. doi:10.1200/JCO.2016.68.2518.
1 2  Schnipper, Lowell E.; Davidson, Nancy E.; Wollins, Dana S.; Tyne, Courtney; Blayney, Douglas W.; Blum, Diane; Dicker, Adam P.; Ganz, Patricia A.; Hoverman, J. Russell. . Journal of Clinical Oncology. 2015-08-10, 33 (23): 2563–2577. PMC 5015427 . PMID 26101248. doi:10.1200/JCO.2015.61.6706.
↑  Cherny, N. I.; Dafni, U.; Bogaerts, J.; Latino, N. J.; Pentheroudakis, G.; Douillard, J.-Y.; Tabernero, J.; Zielinski, C.; Piccart, M. J. . Annals of Oncology. 2017-09-04, 28 (10): 2340–2366. ISSN 0923-7534. PMID 28945867. doi:10.1093/annonc/mdx310 （英语）.
↑  Cherny, N. I.; Sullivan, R.; Dafni, U.; Kerst, J. M.; Sobrero, A.; Zielinski, C.; Vries, De; E, E. G.; Piccart, M. J. . Annals of Oncology. 2017-11-01, 28 (11): 2901–2905  [2020-10-04]. ISSN 0923-7534. PMID 27604385. doi:10.1093/annonc/mdw258. （原始内容存档于2019-08-28） （英语）.
↑  Vivot, A.; Jacot, J.; Zeitoun, J.-D.; Ravaud, P.; Crequit, P.; Porcher, R. . Annals of Oncology. 2017-05-01, 28 (5): 1111–1116. ISSN 0923-7534. PMID 28453694. doi:10.1093/annonc/mdx053 （英语）.
↑  Sudden Price Spikes in Off-Patent Drugs: Perspectives from the Front Lines （页面存档备份，存于） United States Senate Special Committee on Aging, December 9, 2015, retrieved 2 February 2016
↑  Gingery, Derrick. . OTC Markets Group. 24 July 2017  [27 July 2017].
1 2 3  . LegiScan. （原始内容存档于2020-11-03）.
↑  . California Legislative Information. 10 September 2017  [7 August 2018]. （原始内容存档于2021-02-12）.
↑  Menon, Devidas. . Health Affairs. June 2001, 20 (3): 92–103. PMID 11585186. doi:10.1377/hlthaff.20.3.92.
↑  The Severyn Group,Inc.  (PDF). AARP. 2003. （原始内容 (PDF)存档于2011-07-09）.
↑  .   [2020-10-04]. （原始内容存档于2020-10-20）.
↑  Transparency And Drug Prices: Will The New U.S. Mandate On TV Ads Drive Costs Down?
↑  . Academy of Managed Care Pharmacists. 2015. （原始内容存档于2019-04-29）.
↑  Rabbani, A; Alexander GC. . Applied Health Economics and Health Policy. 2009, 7 (4): 255–264  [10 November 2011]. PMID 19905039. doi:10.1007/bf03256159. （原始内容存档于2017-03-25）.
↑   (PDF). AHA. 2015. （原始内容 (PDF)存档于2017-06-08）.
↑  Love, Robert. . AARP. 2017. （原始内容存档于2021-03-10）.
↑  Zullo, Andrew R.; Dore, David D.; Galárraga, Omar. . Journal of Pharmaceutical Health Services Research. March 2015, 6 (1): 33–41. PMC 4930104 . PMID 27375777. doi:10.1111/jphs.12088.
↑  American Hospital Association